Xeltis
- Industry
- Medical Devices and Equipment
- Founded Year
- 2006
- Headquarters
- Eindhoven, The Netherlands
- Employee Count
- 0
Key People
-
Eliane Schutte - Chief Executive Officer
Email: info@xeltis.com
-
Paulo Neves - Chief Medical Officer
Email: info@xeltis.com
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: Experienced leadership with a track record in MedTech.
Eliane Schutte, CEO, has over 25 years in MedTech and biotech industries, including roles at The Medicines Company and IsoTis Orthobiologics. Paulo Neves, CMO, brings extensive experience as a cardiac surgeon and medical lead in MedTech companies.
- Clinical Need
-
Aspect: Very Strong
Summary: Addresses significant unmet needs in vascular access for hemodialysis.
Xeltis' aXess device aims to provide a new, permanent, living vessel for hemodialysis vascular access, potentially reducing complications associated with current options.
- Competition
-
Aspect: First mover
Summary: Pioneering endogenous tissue restoration in vascular implants.
Xeltis is introducing a novel approach with its ETR platform, facing minimal direct competition but requiring significant market education.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing bioabsorbable implants that enable tissue restoration.
The technology involves creating implants that are gradually replaced by the patient's own tissue, a complex and innovative process.
- Patent
-
Aspect: Very Strong
Summary: Robust patent portfolio protecting proprietary technology.
Xeltis has secured patents covering its ETR platform and related technologies, ensuring protection against competitors.
- Financing
-
Aspect: Well-funded
Summary: Secured significant funding from reputable investors.
Raised 32 million in Series D2 funding, with investors including Grand Pharma and DaVita Venture Group.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Engaged in pivotal trials with FDA Breakthrough Device Designation.
Completed enrollment in EU pivotal trial for aXess and received FDA Breakthrough Device Designation, indicating promising regulatory progress.
Opportunity Rollup
- Odds of Success
- 3.05
- Peak Market Share
- 3.55
- Segment CAGR
- 5.1%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Aortic and Vascular Graft Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.18 |
| 2 | 0.53 |
| 3 | 1.24 |
| 4 | 2.48 |
| 5 | 3.55 |
Key Takeaway
Xeltis' innovative ETR platform addresses a significant clinical need with strong leadership and funding, but faces challenges in market adoption and technical complexity.